(PARAGRAPH 1) OSE Immunotherapeutics SA (OSE) saw its position strengthened after partner Veloxis Pharmaceuticals Inc. received a second U.S. Food and Drug Administration Orphan Drug Designation in 2026 for the drug pegrizeprument, this time for preventing heart transplant rejection. The designation follows a similar grant in January for the prevention of liver transplant rejection.
(PARAGRAPH 2) "Pegrizeprument is expected to have a dual mechanism of action where in a direct manner, it blocks CD28-mediated T cell activation, and indirectly, it allows for CTLA-4 mediated immunosuppressive functions," OSE Immunotherapeutics said in a statement detailing the drug's potential.
(PARAGRAPH 3) The FDA grants orphan status to drugs targeting diseases that affect fewer than 200,000 people in the United States. This designation provides incentives including tax credits for clinical trials and seven years of market exclusivity upon approval. Pegrizeprument, a monoclonal antibody fragment, works by blocking CD28-mediated T-cell activation, a key step in organ rejection, without interfering with the immunosuppressive CTLA-4 pathway.
(PARAGRAPH 4) For OSE Immunotherapeutics, the designation de-risks a key partnered asset and increases its commercial value ahead of a potential market launch. While Veloxis is responsible for development and commercialization costs under a 2021 licensing deal, OSE stands to receive future milestone payments and royalties, making the drug's success a direct, low-cost tailwind for the French biotech company.
Pegrizeprument (also known as VEL-101 or FR104) represents a targeted approach in transplant immunology. Unlike some conventional immunosuppressants that have broader effects, it specifically targets the CD28 co-stimulation pathway. This pathway is critical for the activation of effector T-cells that lead to organ rejection.
By blocking CD28, the drug aims to prevent the immune system from attacking the transplanted organ. Crucially, it does so without blocking CTLA-4, a protein that helps maintain immune tolerance. This selective mechanism could potentially offer a better safety profile and more durable protection compared to less targeted therapies.
The development highlights OSE Immunotherapeutics' strategy of advancing a pipeline in immuno-oncology and immuno-inflammation and then partnering assets with larger firms for late-stage development and commercialization. OSE originally discovered and developed pegrizeprument before licensing it to Veloxis in April 2021 for all transplant-related indications.
This model allows OSE to focus on its core strength of early-stage research while leveraging partners' financial and logistical scale to bring drugs to market. The company's cash runway for its internal programs was not disclosed. The success of partnered assets like pegrizeprument provides non-dilutive funding and validation for its discovery platform.
This article is for informational purposes only and does not constitute investment advice.
